Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

ABSTRACT:

Background

The BRAF^V600E mutation is the most common somatic mutation in thyroid cancer. The mechanism associated with BRAF-mutant tumor aggressiveness remains unclear. Lysyl oxidase (LOX) is highly expressed in aggressive thyroid cancers, and involved in cancer metastasis. The objective was to determine whether LOX mediates the effect of the activated MAPK pathway in thyroid cancer.

Methods

The prognostic value of LOX and its association with mutated BRAF was analyzed in The Cancer Genome Atlas and an independent cohort. Inhibition of mutant BRAF and the MAPK pathway, and overexpression of mutant BRAF and mouse models of BRAF^V600E were used to test the effect on LOX expression.

Results

In The Cancer Genome Atlas cohort, LOX expression was higher

SUBMITTER: Boufraqech M 

PROVIDER: S-EPMC6352555 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature